Abstract:S3.5 Environmental exposure - risk for human fungal disease, September 21, 2022, 4:45 PM - 6:15 PMObjectivesThe development of new antifungal drugs will help to expand the limited antifungal arsenal and curb the emergence of drug resistance. To meet the demand for novel antifungal drugs, we performed a high-throughput screen of an FDA-approved compound library (HY-L022, MCE®) and identified a promising lead antifungal compound, otilonium bromide (OTB).MethodsWe determined antifungal activity of each compound from the library and investigated the antifungal spectrum of OTB using broth microdilution assays (Fig. 1a). We tested the fungicidal effect of OTB by the spot assay and disk diffusion assay. The inhibitory effect of OTB on mycelial growth was identified by observing hyphal growth in hyphal-inducing media containing OTB. The antibiofilm activity of OTB was evaluated by XTT method. We further checked the antifungal activity of OTB in vivo by a murine C. albicans infection model, which was constructed by immunosuppression of mice with cyclophosphamide, inhibiting the intestinal microorganisms by levofloxacin (14 mg/ml), and then gavage with C. albicans cells (1 × 108 cells per mouse). A total of 24 C57 mice were randomly divided into three groups: one group was gavaged with saline, one group with 1 mg/kg fluconazole, and one group with 50 mg/kg OTB. In all 2 h after infection, drugs were given once a day for 4 consecutive days, with 15 days of observation. The death of a mouse was assessed daily and statistically analyzed by Log-rank (Mantel-Cox) test. The toxicity of OTB to human cloned colon adenocarcinoma cells was assessed with MTT method.ResultsWe found that OTB is the most promising lead antifungal molecule among FDA-approved drugs (Fig. 1a). OTB has a broad-spectrum antifungal activity with minimum inhibitory concentration for inhibiting the growth of 50% of strains (MIC50) values ranging from 0.39 to 6.25 μ m (Fig. 1b). We found that OTB (≥3.5 μ m ) has fungicidal effect on C. albicans using spot assay (Fig. 1c). We further found that OTB (25 μ g/disk) can form a clear inhibition zone, but not fluconazole (25 μ g/disk) (Fig. 1d). Besides, we spotted C. albicans cells from the broth microdilution assays onto YPD solid medium and found that cells treated with OTB (≥1.56 μ m ) could not recover on YPD solid medium, while cells treated with FLC could (Fig. 1e). It is worth noting that OTB has inhibitory effects on filamentation and biofilm formation at 12.5 μ m (Fig. 2a, b), which are key virulence factors of pathogenic fungi. Besides, OTB (50 mg/kg) significantly prolonged the median survival time from 5 days (control group) to 15 days and improved the survival rate from 0% (control group) to 62.5% ( P = .0078) (Fig. 2c). Furthermore, we found that OTB exhibited relative low toxicity to mammal cells with IC50 28-57 μ m (Fig. 2d), which was much higher than MIC50 against pathogenic fungi.ConclusionOur study highlights that OTB has a broad-spectrum antifungal activity with low MIC50 values and high safety in vitro and potent antifungal efficacy in vivo and will be beneficial to the treatment of devastating invasive fungal infections.

Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- Benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis

Design, Synthesis, and Antifungal Activity of 3-Substituted-2( 5H )-Oxaboroles

Design, synthesis, and biological evaluation of novel boron-containing azoles as potential antifungal agents

Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum

Design, synthesis, and evaluation of novel tetrazoles featuring isoxazole moiety as highly selective antifungal agents

Terbinafine: An oral and topical antifungal agent

Discovery of Novel 8-Hydroxyquinoline Derivatives with Potent In Vitro and In Vivo Antifungal Activity

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Novel Fluorinated 7-Hydroxycoumarin Derivatives Containing an Oxime Ether Moiety: Design, Synthesis, Crystal Structure and Biological Evaluation

Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Discovery of highly potent triazole derivatives with broad-spectrum antifungal activity based on Iodiconazole

Discovery of Novel Tetrazoles Featuring a Pyrazole Moiety as Potent and Highly Selective Antifungal Agents

Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis—Results of an in vitro investigation

Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy

Design, synthesis and inhibitory activity against Candida albicans of a series of derivatives with 5-nitrofuran scaffold

Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Fluconazole-Based Compounds with Promising Antifungal Activities

Progess of topical antifungal agents for the treatment of onychomycosis

"Click" amphotericin B in prodrug nanoformulations for enhanced systemic fungemia treatment

Discovery of Simplified Sampangine Derivatives As Novel Fungal Biofilm Inhibitors.

S3.5d Identification of fungicidal activity of otilonium bromide by the repurposing approach

Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections